Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02715804 · ClinicalTrials.gov registry record · Phase 3
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
A Phase 3 study, sponsored by Halozyme Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 492
- Enrollment target
NCT02715804: Clinical Trial Phase 3 study, sponsored by Halozyme Therapeutics.
NCT02715804 is a Phase 3 study that was terminated before completion, run by Halozyme Therapeutics. The registered enrollment target is 492 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02715804, a Phase 3 study, was terminated before completion, sponsored by Halozyme Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 492 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA).
Primary Outcome
Overall survival was defined as the time from randomization until death from any cause. Overall survival was analyzed using Kaplan-Meier methods.
Interventions
- DRUG Placebo
- DRUG Gemcitabine
- DRUG nab-Paclitaxel
- OTHER Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2016-03-14 |
| Est. Completion | 2019-11-04 |
| Phase | Phase 3 |
Why NCT02715804 stopped before completion
NCT02715804 is an interventional study that assigns participants to a tested intervention. The registered 492 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02715804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02715804 about?
NCT02715804 is a clinical study titled "A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma". The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (H...
What is the current status of trial NCT02715804?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2016-03-14. Estimated completion is 2019-11-04.
What interventions are being tested in trial NCT02715804?
The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), nab-Paclitaxel (DRUG), Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20) (OTHER).
Who is sponsoring clinical trial NCT02715804?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02715804's enrollment target sits among peer trials
492 780th of 2000 higher than 1,220 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI